Photo of Hadine Joffe, MD MSc

Hadine Joffe, MD MSc

Brigham And Women's Hospital

Brigham And Women's Hospital

Photo of Hadine Joffe, MD MSc

Brigham And Women's Hospital

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Hadine Joffe, MD MSc but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Hadine Joffe, MD MSc

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Paula A. Johnson Professor of Psychiatry in the Field of Women's Health, Psychiatry, Harvard Medical School
  • Dana Farber Harvard Cancer Center Breast Cancer Program, Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute
  • Executive Vice Chair for Academic and Faculty Affairs, Department of Psychiatry, Brigham And Women's Hospital
  • Director, Women's Hormone and Aging Research Program, Department of Psychiatry, Brigham And Women's Hospital
  • Executive Director, Mary Horrigan Connors Center for Women's Health and Gender Biology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My primary research interest is in the mechanisms, inter-relationships, and treatment of menopausal symptoms in healthy women and women with breast cancer. My work focuses on the neuroendocrine mechanisms underlying hot flashes and the impact of hot flashes on sleep and mood. These studies are conducted using experimental models of induced hot flashes (i.e., gonadotropin-releasing hormone agonists) and in women initiating tamoxifen, aromatase inhibitors, and other anti-estrogen therapies to treat or reduce the risk of breast cancer. In other work, I conduct clinical trials and intervention studies to determine optimal therapy for hot flashes, insomnia, and depression, and to understand whether targeting of specific menopausal symptoms is central to optimization of well-being in women with hot flashes. We assess hot flashes using subjective approaches (diaries) and objective methodologies (skin-conductance monitoring) and sleep using subjective measures of sleep quality and objective measures of sleep (actigraphy, polysomnography).

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Bower JE, Partridge AH, Wolff AC, Thorner ED, Irwin MR, Joffe H, Petersen L, Crespi CM, Ganz PA. Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. J Clin Oncol 2021; 39:3473-3484. PubMed
  • Gold EB, Crawford SL, Leung K, Greendale G, Reeves KW, Joffe H, Avis NE. Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN. Breast Cancer Res Treat 2021. PubMed
  • Van Dyk K, Joffe H, Carroll JE. Sleep and endocrine therapy in breast cancer. Curr Opin Endocr Metab Res 2021; 18:165-170. PubMed
  • Ganz PA, Bower JE, Partridge AH, Wolff AC, Thorner ED, Joffe H, Irwin MR, Petersen L, Crespi CM. Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. JNCI Cancer Spectr 2021; 5:pkab017. PubMed
  • Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, Saponara M, Orsolini G, Zagami P, Nicolo E, De Marinis F, Tortora G, Bria E, Minucci S, Joffe H, Veronesi P, Wargo JA, Rosenthal R, Swanton C, Mantovani A, Gelber RD, Viale G, Goldhirsch A, Giaccone G. Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion. Clin Cancer Res 2021. PubMed
  • Hickey M, Moss KM, Brand A, Wrede CD, Domchek SM, Meiser B, Mishra GD, Joffe H. What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecol Oncol 2021. PubMed
  • Yusufov M, Nathan M, Wiley A, Russell J, Partridge A, Joffe H. Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients. Breast Cancer Res Treat 2020. PubMed
  • Diem SJ, Joffe H, Larson JC, Tsai JN, Guthrie KA, LaCroix AZ, Ensrud KE, Freeman EW, Leder BZ. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J Clin Endocrinol Metab 2014. PubMed
  • Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, Freeman EW, Larson JC, Manson JE, LaCroix AZ, Guthrie KA. Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial. Obstet Gynecol 2014. PubMed
  • Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, Newton KM, Freeman EW, Anderson GL, Larson JC, Hunt J, Shifren J, Rexrode KM, Caan B, Sternfeld B, Carpenter JS, Cohen L. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014. PubMed
  • Sharkey KM, Crawford SL, Kim S, Joffe H. Objective sleep interruption and reproductive hormone dynamics in the menstrual cycle. Sleep Med 2014; 15:688-93. PubMed
  • Looby SE, Shifren J, Corless I, Rope A, Pedersen MC, Joffe H, Grinspoon S. Increased hot flash severity and related interference in perimenopausal human immunodeficiency virus-infected women. Menopause 2014; 21:403-9. PubMed
  • Su HI, Maas K, Sluss PM, Chang RJ, Hall JE, Joffe H. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women. J Clin Endocrinol Metab 2013; 98:E1961-6. PubMed
  • Joffe H, Crawford S, Economou N, Kim S, Regan S, Hall JE, White D. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep. Sleep 2013; 36:1977-85. PubMed
  • Joffe H, Guthrie KA, Larson J, Cohen LS, Carpenter JS, Lacroix AZ, Freeman EW. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network. Menopause 2013; 20:261-8. PubMed
  • Joffe H, Deckersbach T, Lin NU, Makris N, Skaar TC, Rauch SL, Dougherty DD, Hall JE. Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study. J Clin Endocrinol Metab 2012; 97:3207-15. PubMed
  • Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, Sternfeld B, Lacroix AZ, Landis CA, Woods NF, Freeman EW. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause 2012. PubMed
  • Joffe H, Chang Y, Dhaliwal S, Hess R, Thurston R, Gold E, Matthews KA, Bromberger JT. Lifetime history of depression and anxiety disorders as a predictor of quality of life in midlife women in the absence of current illness episodes. Arch Gen Psychiatry 2012; 69:484-92. PubMed
  • Rogines-Velo MP, Heberle AE, Joffe H. Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy. Menopause 2012; 19:471-5. PubMed
  • Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2012; 119:527-38. PubMed
  • Joffe H, Petrillo LF, Koukopoulos A, Viguera AC, Hirschberg A, Nonacs R, Somley B, Pasciullo E, White DP, Hall JE, Cohen LS. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab 2011; 96:E1044-54. PubMed
  • Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, Carpenter JS, Anderson GL, Larson JC, Ensrud KE, Reed SD, Newton KM, Sherman S, Sammel MD, LaCroix AZ. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305:267-74. PubMed
  • Greendale GA, Wight RG, Huang MH, Avis N, Gold EB, Joffe H, Seeman T, Vuge M, Karlamangla AS. Menopause-associated symptoms and cognitive performance: results from the study of women's health across the nation. Am J Epidemiol 2010; 171:1214-24. PubMed
  • Joffe H, Petrillo L, Viguera A, Koukopoulos A, Silver-Heilman K, Farrell A, Yu G, Silver M, Cohen LS. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010; 202:171.e1-171.e11. PubMed
  • Thurston RC,Bromberger JT,Joffe H,Avis NE,Hess R,Crandall CJ,Chang Y,Green R,Matthews KA. Beyond frequency: who is most bothered by vasomotor symptoms? Menopause 2008; 15:841-7. PubMed
  • Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause ; 17:908-16. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Hadine Joffe, MD MSc but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members